The Promise Of AAV Gene Therapy With REGENXBIO's Ken Mills
Source: Cell & Gene
Ken Mills, CEO, President, and Director at REGENXBIO joins Erin Harris for this episode of Cell & Gene: The Podcast to discuss the company's progress with its Phase I/II Affinity Duchenne trial of RGX-202 for the treatment of Duchenne Muscular Dystrophy. They discuss the future of AAV gene therapy as well as achieving scalability with consistent yield and product purity in gene therapy manufacturing.
Find Cell & Gene: The Podcast wherever you get your podcasts.
This website uses cookies to ensure you get the best experience on our website. Learn more